BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Years
Key Takeaways
Open-label extension (OLE) results from the phase 3b BE RADIANT trial suggest bimekizumab was associated with rapid improvements in patient-reported itching, skin pain, and scaling compared with secukinumab at week 4 and year 1.
Higher proportions of bimekizumab-randomized patients achieved concurrent PASI = 0 and DLQI 0/1 through 1 year, and responses maintained to 3 years in the open-label extension.
Patients switching from secukinumab to bimekizumab showed improved patient-reported and quality-of-life outcomes after the transition.
Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to severe plaque psoriasis, according to data from the BE RADIANT trial and its 3-year open-label extension (OLE) study.
Investigators randomized 743 patients were randomized to bimekizumab (n = 373) or secukinumab (n = 370). During the 48-week double-blind period, patients received bimekizumab 320 mg every 4 weeks (Q4W) to week 16, then Q4W or every 8 weeks (Q8W), or secukinumab 300 mg Q4W. At week 48, 336 bimekizumab-randomized and 318 secukinumab-randomized patients entered the OLE. All patients transitioned to bimekizumab Q8W by week 64.
Improvements in Psoriasis Symptoms and Impacts Measure (P-SIM) domains were reported at week 4. Among bimekizumab- vs secukinumab-randomized patients, 34.0% vs 25.1% reported no itching; 74.5% vs. 60.0% no skin pain; and 46.1% vs. 21.6% no scaling. The results showed higher proportions of bimekizumab-randomized patients reporting complete resolution of itching (60.9% vs 48.1%; nominal P < 0.001), skin pain (78.6% vs 70.8%; nominal P = 0.01), and scaling (70.5% vs. 49.7%; nominal P < 0.001).
Concurrent achievement of PASI = 0 and DLQI 0/1 was more frequent with bimekizumab at week 4 (11.5% vs. 4.6%; nominal P < 0.001) and year 1 (61.7% vs. 42.7%; nominal P < 0.001). At OLE entry, 69.2% of continuous bimekizumab-treated patients and 48.5% of those switching from secukinumab achieved PASI = 0 and DLQI 0/1. After switching, responses increased in the secukinumab/bimekizumab group, with rates maintained to year 3 (62.2% and 63.8%, respectively).
"Many patients treated with bimekizumab had concurrent improvements in clinical outcomes and PROs, both of which are important for informing treatment decisions, suggesting that bimekizumab’s high clinical efficacy translates into benefits to patient-perceived symptoms and health-related quality of life," the authors added in the study.
Soure: Augustin M, et al. JAMA Dermatology. 2026. Doi:10.1001/jamadermatol.2025.6055